PDCD1 and lung cancer: Another innovative nanomedicine, SGT-53—a plasmid DNA nanocomplex carrying wild-type human TP53—has been shown to augment the antitumor efficacy of PD-1 blockade in TP53-matched, PD-1-resistant lung cancer mouse models.